Skip to main content

Advertisement

SpringerLink
Log in

Patient and physician preferences for type 2 diabetes medications: a systematic review

  • Review article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Background

There are several treatments to cure type 2 diabetes (T2D) and every one of them has certain attributes which is lead patients and specialists to have different preferences and select power. Therefore, we did this systematic study to evaluate patients̓ and physicians̓ preferences for type 2 diabetes medications by extracting attributes of anti-diabetic medications and identifying their relative importance.

Methods

We searched the PubMed, Ovid, Web of science, Scopus and Embase databases for articles which have been published on or before May 8th, 2018(The start time of the search in our study was May 8th, 2018).

Results

The searches identified 3346 studies, of which 17 (from 2009 to 2017) were included in the final synthesis and 27 attributes of type 2 anti-diabetic have been investigated. The most important attributes are changes of blood glucose and HbA1c level, hypoglycemia events, weight changes, gastrointestinal complications, cardiovascular effects, medicines cost, and administration mode and dosage of medicines.

Conclusion

physicians and patients prefer antidiabetics which is reduce blood glucose and HbA1c level effectively and have low side effects too (hypoglycemic event, cardiovascular and gastrointestinal). The effect of weight reduction, low cost, low dosing and low frequency of using. Health care providers, Specialist, and manufacturers should consider to these attributes in treatment process and marketing. It can increase adherence to management approaches, and reduce morbidity of patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–83.

    Article  CAS  PubMed  Google Scholar 

  2. García-Pérez L-E, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013;4(2):175–94.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Wabe NT, Angamo MT, Hussein S. Medication adherence in diabetes mellitus and self management practices among type-2 diabetics in Ethiopia. N Am J Med Sci. 2011;3(9):418.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Kassahun A, Gashe F, Mulisa E, Rike WA. Nonadherence and factors affecting adherence of diabetic patients to anti-diabetic medication in Assela general hospital, Oromia region, Ethiopia. J Pharm Bioall Sci. 2016;8(2):124–9.

    Article  CAS  Google Scholar 

  5. Habte BM, Kebede T, Fenta TG, Boon H. Barriers and facilitators to adherence to anti-diabetic medications: Ethiopian patients' perspectives. African PHCFM. 2017;9(1):1–9.

    Article  Google Scholar 

  6. Association AD. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S73–85.

    Article  Google Scholar 

  7. Mühlbacher AC, Juhnke C. Patient preferences versus physicians’ judgement: does it make a difference in healthcare decision making? Applied Health Economics and Health Policy. 2013;11(3):163–80.

    Article  PubMed  Google Scholar 

  8. Johnson FR, Hauber B, Siegel CA, Hass S, Sands BE. Are gastroenterologists less tolerant of treatment risks than patients? Benefit-risk preferences in Crohn's disease management. J Manag Care Pharm. 2010;16(8):616–28.

    Article  PubMed  Google Scholar 

  9. Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly GS, et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Int J Technol Assess Health Care. 2009;25(3):359–66.

    Article  PubMed  Google Scholar 

  10. Feher MD, Brazier J, Schaper N, Vega-Hernandez G, Nikolajsen A, Bøgelund M. Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. BMJ Open Diabetes Res Care. 2016;4(1):e000192.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Poulos C, González JM, Lee LJ, Boye KS, Johnson FR, Bae JP, et al. Physician preferences for extra-glycemic effects of type 2 diabetes treatments. DRC. 2013;4(2):443–59.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mark TL, Swait J. Using stated preference and revealed preference modeling to evaluate prescribing decisions. Health Econ. 2004;13(6):563–73.

    Article  PubMed  Google Scholar 

  13. Discrete Choice Experiment (DCE) [online]. 2016.

  14. Scott A. Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. J Econ Psychol. 2002;23(3):383–98.

    Article  Google Scholar 

  15. Bøgelund M, Vilsbøll T, Faber J, Henriksen JE, Gjesing RP, Lammert M. Patient preferences for diabetes management among people with type 2 diabetes in Denmark–a discrete choice experiment. Curr Med Res Opin. 2011;27(11):2175–83.

    Article  PubMed  Google Scholar 

  16. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

  17. Beelmann A. Review of systematic reviews in the social sciences: A practical guide. European Psychologist.2006;11(3):244–245.

  18. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6(12):e011458.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Porzsolt F, Clouth J, Deutschmann M, Hippler H-J. Preferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care values. Health Qual Life Outcomes. 2010;8(1):125.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Mansfield C, Sikirica MV, Pugh A, Poulos CM, Unmuessig V, Morano R, et al. Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365–78.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mühlbacher A, Bethge S. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ. 2016;17(9):1125–40.

    Article  PubMed  Google Scholar 

  22. Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, et al. Patients’ and physicians’ preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Preference Adher. 2015;9:1443.

  23. Gelhorn H, Stringer S, Brooks A, Thompson C, Monz B, Boye K, et al. Preferences for medication attributes among patients with type 2 diabetes mellitus in the UK. Diabetes Obes Metab. 2013;15(9):802–9.

    Article  CAS  PubMed  Google Scholar 

  24. Mohamed A, Zhang J, Johnson F, Lomon ID, Malvolti E, Townsend R, et al. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. Diabetes Metab. 2013;39(5):397–403.

    Article  CAS  PubMed  Google Scholar 

  25. Lloyd A, Nafees B, Barnett AH, Heller S, Ploug UJ, Lammert M, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Ther. 2011;33(9):1258–67.

    Article  PubMed  Google Scholar 

  26. Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å, Bøgelund M. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin. 2010;26(4):917–23.

    Article  CAS  PubMed  Google Scholar 

  27. Hauber A, Mohamed A, Johnson F, Falvey H. Treatment preferences and medication adherence of people with type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.

    Article  CAS  PubMed  Google Scholar 

  28. Flood EM, Bell KF, de la Cruz MC, Ginchereau-Sowell FM. Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin. 2017;33(2):261–8.

    Article  CAS  PubMed  Google Scholar 

  29. Hauber AB, Tunceli K, Yang J-C, Gantz I, Brodovicz KG, Alexander CM, et al. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Therapy. 2015;6(1):75–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Hauber AB, Nguyen H, Posner J, Kalsekar I, Ruggles J. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin. 2016;32(2):251–62.

    Article  CAS  PubMed  Google Scholar 

  31. Polster M, Zanutto E, McDonald S, Conner C, Hammer M. A comparison of preferences for two GLP-1 products–liraglutide and exenatide–for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.

    Article  PubMed  Google Scholar 

  32. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetologia. 2018;61(12):2461–98.

    Article  PubMed  Google Scholar 

  33. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–5.

    Article  CAS  PubMed  Google Scholar 

  34. van Wijngaarden RP, Overbeek JA, Heintjes EM, Schubert A, Diels J, Straatman H, et al. Relation between different measures of glycemic exposure and microvascular and macrovascular complications in patients with type 2 diabetes mellitus: an observational cohort study. Diabetes Ther. 2017;8(5):1097–109.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Larkin AT, Hoffman C, Stevens A, Douglas A, Bloomgarden Z. Determinants of adherence to diabetes treatment. J Diabetes. 2015;7(6):864–71.

    Article  PubMed  Google Scholar 

  36. Misra A, Tandon N, Ebrahim S, Sattar N, Alam D, Shrivastava U, et al. Diabetes, cardiovascular disease, and chronic kidney disease in South Asia: current status and future directions. BMJ (British medical journal). 2017;357:j1420.

    Article  Google Scholar 

  37. Bray GA. Medical consequences of obesity. The Journal of Clinical Endocrinology & Metabolism. 2004;89(6):2583–9.

    Article  CAS  Google Scholar 

  38. Han T, Tijhuis M, Lean M, Seidell J. Quality of life in relation to overweight and body fat distribution. Am J Public Health. 1998;88(12):1814–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wilding J. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68(6):682–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Matza LS, Yurgin N, Boye KS, Malley K, Shorr JM. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. Curr Med Res Opin. 2007;23(9):2051–62.

    Article  PubMed  Google Scholar 

  41. Alsahli M, Gerich JE. Hypoglycemia. Endocrinology and metabolism clinics of North America. 2013;42(4):657–76.

    Article  PubMed  Google Scholar 

  42. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. JDMD (journal of diabetes & metabolic disorders). 2012;11(1):17.

  43. Ortiz MR. Hypoglycemia in Diabetes. The Nursing clinics of North America. 2017;52(4):565–74.

    Article  Google Scholar 

  44. Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes. 2013;4(3):51–63.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bommer C, Heesemann E, Sagalova V, Manne-Goehler J, Atun R, Bärnighausen T, et al. The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endo. 2017;5(6):423–30.

    Article  Google Scholar 

  47. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.

    Article  CAS  PubMed  Google Scholar 

  48. Lazaro A, Barberan R, Rubio E. Private and social time preferences for health and money: an empirical estimation. Health Econ. 2001;10(4):351–6.

    Article  CAS  PubMed  Google Scholar 

  49. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2015;38(1):140–9.

    Article  Google Scholar 

  50. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(5):1218–24.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was part of Mahdi Toroski PhD thesis.

Author information

Authors and Affiliations

  1. Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Mahdi Toroski, Abbas Kebriaeezadeh, Hadi Abbasian & Shekoufeh Nikfar

  2. Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Abbas Kebriaeezadeh

  3. Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Alireza Esteghamati

  4. School of Public Health, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Ali Kazemi Karyani

Authors
  1. Mahdi Toroski
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abbas Kebriaeezadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Esteghamati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ali Kazemi Karyani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hadi Abbasian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shekoufeh Nikfar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shekoufeh Nikfar.

Ethics declarations

Conflict of interest

Authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toroski, M., Kebriaeezadeh, A., Esteghamati, A. et al. Patient and physician preferences for type 2 diabetes medications: a systematic review. J Diabetes Metab Disord 18, 643–656 (2019). https://doi.org/10.1007/s40200-019-00449-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-019-00449-4

Keywords

Search

Navigation